Ipsen's Stock Breaks Through Technical Resistance, Up 55% Over the Year
The stock of the French pharmaceutical company traded at 165.20 euros this Wednesday, up 2.99% from the previous day. This increase is part of a sustained upward trend, with a gain of nearly 11% over seven days and more than 55% over a year. The CAC 40, meanwhile, is up 2.12% in the session.
Breaking Technical Resistance
By surpassing the 165.10 euros mark, Ipsen has crossed its resistance threshold identified by technical analysis. This breakthrough above this level is a significant signal, especially since the stock is now well above its 50-day moving average, located at 150.18 euros, and even more so from its 200-day moving average, positioned at 124.90 euros. The gap of more than 25 points between these two moving averages reflects the magnitude of the upward trend that has been underway for several months. The RSI, a momentum indicator measuring the speed of price movements, is at 60, indicating an acceleration zone without reaching the overbought levels usually set beyond 70. The price has also exceeded the upper Bollinger band (164.42 euros), which could signal an extension of short-term volatility. The quarterly performance of nearly 39% demonstrates the strength of the ongoing movement.
Upcoming Financial Milestones
The biopharmaceutical group, specializing in oncology and rare diseases, will publish its first quarter 2026 revenue on April 16, which is in two weeks. This upcoming date is an important milestone to assess the commercial trajectory of the group. The general assembly is scheduled for May 13, followed by the semi-annual results on July 30. In the European pharmaceutical sector, today's session is generally positive. UCB is up 3.17%, while Sanofi advances more modestly by 0.52%. Ipsen thus performs reasonably at midday. The stock has a beta of -0.07, indicating an almost null correlation with major benchmark indices, which distinguishes it in a market environment characterized by a high level of stress on the VIX (31.05 points at the close of March 27). This relatively defensive characteristic may help explain the current appeal of the stock in a tense geopolitical context.
